Healthcare ❯ Pharmaceuticals ❯ Diabetes Treatment

GLP-1 Receptor Agonists

Novo Nordisk Products Mounjaro and Zepbound

Eli Lilly Lowers 2024 Revenue Forecast as Weight-Loss Drug Sales Lag

The pharmaceutical company revises Q4 revenue estimates down by $500 million, citing slower-than-expected sales of key drugs Mounjaro and Zepbound.

Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition